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Human cell cultureBackground: Many human molecular and genetic studies require the use of a renewable biological
material. Although primary fibroblast cell lines can be used for this purpose, there are disadvantages
associated with human biopsies including the limited number of cell divisions. Peripheral blood has
the advantage of being easier to obtain but also the drawback that blood cells produce only short-term
cultures. Epstein-Barr virus is capable of transforming human B lymphocytes into indefinitely proliferat-
ing cells that can be maintained in tissue culture. Here, we report a convenient method of B-lymphocyte
immortalization using small volumes of freshly collected human blood serum saturated with nucleated
blood cells.
Aim of the study: The aim of the present study is modification and improvement of the protocol for highly
efficient immortalization of human B lymphocytes from small volume of blood samples.
Material and methods: Cell line B95-8 was used as Epstein-Barr virus source for viral stock preparation.
Immortalizing medium contains RPMI-1640, viral stock and additives. No feeder layer was used.
Results: As result we present high efficient method for B lymphocytes immortalization with start blood
volume less than 5 ml.
Conclusion: The method is applicable for immortalization of B lymphocytes from small blood samples
and is essential for studies involving children or patients when large blood volume sampling is
impossible.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human blood cell lines are powerful tools for a variety of in vitro
functional and molecular studies and an inexhaustible source of
high molecular weight DNA for genetic disease collections. Cellular
immortalization is defined as the phenotypic transformation of a
normal cell with a limited life span to a malignant one. The
immortalization of mammalian cells can be induced by chemical
carcinogens, transfection of oncogenic viruses, or telomerase reac-
tivation [1,2]. Epstein-Barr virus (EBV) is a human herpesvirus that
causes infectious mononucleosis and is etiologically associated
with Burkitt’s lymphoma and nasopharyngeal carcinoma [3]. Over
the past 40 years, cell line supernatants (e.g., from the marmoset
B-lymphoblastoid cell line B95-8) were commonly used to confirm
the neoplastic potential of EBV infection by virus-mediatedimmortalization of cultured B-lymphocytes from human blood
[4–8]. Traditionally, these techniques require approximately 50
ml peripheral blood for one sample, special kits or media for
B-cell isolation, and the use of feeder cell layers [9]. This is quite
laborious and inapplicable for the immortalization of B-cells
derived from small volumes. Research requiring cell immortaliza-
tion from small sample sizes, for example blood collected from
hyperactive patients or children, often lack the material volume
necessary for immortalization by standard approaches. The aim
of the present study is modification and improvement of the pro-
tocol for highly efficient immortalization of human B lymphocytes
from small volume of blood samples, without feeder cells layer and
virus activating agents.2. Ethics
Patient involvement in this study was strictly designed in accor-
dance with international standards, which include the awareness
of the subject, his or her consent to participate in the study in its
Fig. 1. Blood sample fractionation directly before plasma collection for immortal-
ization. A. Blood plasma with nucleated cells. B. Erythrocyte layer. Important note:
there is no ring of nucleated cells.
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formed to ethical standards developed in accordance with the Hel-
sinki Declaration of the World Medical Association, as amended in
2000. In addition, these studies were supervised by the Institu-
tional Review Board.
3. Materials and methods
3.1. Safety
All experiments with human samples, primate samples, and
virus stock must be performed in a Class 2 BSC in a BSL-2 labora-
tory, by properly trained laboratory personnel wearing appropriate
personal protective equipment including a lab coat, gloves and
safety glasses.
3.2. Viral stock preparation
B95-8 marmoset suspension cell culture from IMCB SB RAS cell
repository was tested for mycoplasma by PCR screening as
previously described [10]. Cells were cultured in RPMI 1640
medium (Gibco, USA) with 20% of Fetal Bovine Serum (Gibco),
4 mM L-glutamine (twice the normal culture concentration)
(Gibco) and 50 lg/ml gentamicin sulfate (KRKA, Slovenia). After
3 days of incubation, supernatant was collected without mixing
the cells and passed through a 0.22 lm membrane filter (Corning,
USA) to remove living marmoset cells.
3.3. Immortalization and freezing medium
Cells were immortalized in a medium containing 50% culture
medium, 50% viral stock, 3% Phytohaemagglutinin-M (Gibco) and
0.04 mg/ml Cyclosporin A (Goldbio, USA). Immortalized cells were
frozen in 90% Fetal Bovine Serum (Gibco) with 10% DMSO (Sigma,
USA).
3.4. Samples
Blood samples were collected in Novosibirsk State Regional
Clinical Diagnostic Center of Ministry of Health of Russian Federa-
tion according to ethical standards. Informed consent was obtained
from every involved individual.
4. Results and discussion
EBV, also known as human herpesvirus 4, is one of the most
common human viruses and the cause of infectious mononucleo-
sis. Most people are infected with EBV at some point in their lives.
Because EBV can sometimes cause malignant degeneration, tests
using IgM (for recent infection) or IgG antibodies directed against
the viral capsid antigen of EBV are often administered as a precon-
dition for a person receiving permission to work.
To initiate the immortalization procedure reported here, we
first thawed 5 million B95-8 marmoset cells infected with EBV in
10 ml culture medium, and 10–15 ml of fresh medium was added
twice a week. Every three days, supernatant was collected without
cell mixing and filtered for viral stock preparation. Note that it is
important not to use inactivated bovine serum.
For immortalization, we used 3–5 ml blood samples collected in
heparin test tubes (Vacutest, Kima, Italia). Blood must be at room
temperature rather than chilled. One hour before culturing, it is
necessary to mix and exfoliate the blood, but do not allow com-
plete stratification into 3 layers (Fig. 1).
After this partial separation, we transferred the plasma contain-
ing nucleated cells into vertically oriented T25 flasks and added 9ml of immortalization medium. One week later, we removed
approximately half of this medium and replaced it with an equal
volume of pre-warmed fresh growth medium containing 1–3%
phytohaemagglutinin-M. Flasks should be incubated in an upright
position with vented or loose caps at 37 C in a CO2 incubator.
Important note: for the first four weeks, cells should be maintained
by partially removing the growth medium without centrifugation
based on its gradual acidification (i.e., when the color changes to
yellow). The volume of medium in the flask can affect the growth
of cells as the surface to air ratio is important in maintaining the
proper pH of the medium. No more than 20 ml of medium should
be used in a T25 flask. Cells are cultured in a medium containing
virus and cyclosporine A for the first week; after this, growth med-
ium should only be supplemented with 1% phytohaemagglutinin.
When the cells begin to form conglomerates and the number of
cells doubles or triples twice a week, one can conclude that the
culture is immortal. Establish the malignancy of cells as soon as
possible, and then freeze the cells in a freezing medium using a
1 C/min Slow Rate Freezing Container (Biocision). Vials contain-
ing immortalized cells should be stored at 70 C and then trans-
ferred to a liquid nitrogen cell bank.
Traditionally, MRC-5 irradiated feeder cells are used during this
process [11,6,9], which help to nourish the plasma cells during the
transformation growth phase and possibly produce growth factors.
In contrast, our method is feeder free. Plasma-containing cells can
be used as a source of human serum and thus provide a number of
advantages when grown in culture.
During the first week of incubation, Cyclosporin A suppresses
the in vitro immune response of T-cells to the presence of EBV,
but after 1 week this chemical must be removed. Generally, we
see the steady formation of immortalized colonies by the third or
fourth week. Freezing during these early stages allows the avoid-
ance of cell subcloning.
Another advantage of our protocol is that it is not necessary to
treat the B95-8 cell line with chemical agents (e.g., 12–0-tetra-de
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butyric acid) to induce viral production [12,13]. Perhaps this is
because both cultured cells and virus are actively multiplying dur-
ing the active growth phase. For small sample sizes, our method
has the advantage that immortalization occurs in more than 90%
of the time, which is essential when working with children or in
other situations when one is unable to draw a large volume of
blood.5. Conclusion
Traditionally, immortalization require approximately 50 ml
peripheral blood for one sample, special kits or media for B-cell iso-
lation, and the use of feeder cell layers. This reproducible method is
feeder free and activator of viral production free. It is easy to use
and require small volumes of peripheral blood.Acknowledgments
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